Sino Biopharmaceutical (HK:1177) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Sino Biopharmaceutical has announced positive results from its Phase III study of Benmelstobart Injection combined with chemotherapy, followed by Anlotinib Hydrochloride Capsules as a first-line treatment for advanced squamous non-small cell lung cancer. The interim analysis showed significant improvement in progression-free survival compared to the existing treatment, marking a promising development for patients with this challenging cancer subtype. The company plans to submit a marketing application for this new indication soon, which could offer new hope for cancer treatment.
For further insights into HK:1177 stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- ‘Keep On Buying,’ Says Investor About Microsoft Stock
- ‘Priced for Fantasy,’ Says Investor About Tesla Stock
- ‘Remain Skeptical,’ Says Top Investor About AMD Stock
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
